Preclinical News and Research

RSS

Master Regulator proteins control cancer transcriptional identity

Thousands of different genetic mutations have been implicated in cancer, but a new analysis of almost 10,000 patients found that regardless of the cancer's origin, tumors could be stratified in only 112 subtypes and that, within each subtype, the Master Regulator proteins that control the cancer's transcriptional state were virtually identical, independent of the specific genetic mutations of each patient.

11 Jan 2021

Study: 20% of glioblastomas are fueled by overactive mitochondria

A new study has found that up to 20% of glioblastomas--an aggressive brain cancer--are fueled by overactive mitochondria and may be treatable with drugs currently in clinical trials.

11 Jan 2021

International consortium awarded SNSF Sinergia grant to improve treatment for pediatric brain tumors

SNSF Sinergia grant awarded to research groups in Switzerland and Norway to identify novel treatment strategies for children with aggressive brain tumors.

7 Jan 2021

RNA sequencing data reveals three major molecular subtypes of Alzheimer's disease

Researchers at the Icahn School of Medicine at Mount Sinai have identified three major molecular subtypes of Alzheimer's disease (AD) using data from RNA sequencing.

7 Jan 2021

Study opens the way for a potential new cure for children with hard-to-treat neuroblastoma

Researchers at the University of Gothenburg now suggest a possible cure for children with hard-to-treat forms of neuroblastoma using a new combination of drugs.

7 Jan 2021

MD Anderson and Xencor to develop novel antibody therapeutics to treat cancer patients

The University of Texas MD Anderson Cancer Center and Xencor, Inc. today announced a strategic research collaboration and commercialization agreement to develop novel CD3 bispecific antibody therapeutics for the potential treatment of patients with cancer.

7 Jan 2021

CytoDel successfully delivers neuronal antibody in animal models of botulism

CytoDel, Inc., a privately-held corporation, today announces the publication of preclinical data on the Company's lead product, Cyto-111, in the peer-reviewed journal, Science Translational Medicine. The complete text of the article titled, "Neuronal Delivery of Antibodies has Therapeutic Effects in Animal Models of Botulism," can be found here.

7 Jan 2021

Repurposed drug can treat hearing loss in humans

According to the World Health Organization, around 466 million people worldwide have disabling hearing loss, a number the organization projects will double by 2050 to affect 1 in 10 people.

7 Jan 2021

Understanding traumatic brain injury in women

Analysis from a workshop convened by the National Institute of Neurological Disorders and Stroke (NINDS) in 2017 reveals gaps in and opportunities for research to improve understanding of the effects of traumatic brain injury (TBI) in women.

7 Jan 2021

Main bioactive compound of ginger root may protect against autoimmune disease progression

Naturopathic medicine, or herbal medicine, is all the rage, especially among young people. But how much of this is supported by science?

6 Jan 2021

Are SARS-CoV-2 antibodies associated with disease enhancement?

As SARS-CoV-2 continues to wreak its havoc, antibodies that neutralize the virus and protect against infection have become an important focus of research. However, there is a concern as to whether these antibodies can actually enhance the disease.

6 Jan 2021

Researchers test the effects of growth molecules exuded by oral bacteria

The human body is filled with friendly bacteria. However, some of these microorganisms, such as Veillonella parvula, maybe too nice.

6 Jan 2021

Researchers discover protein crucial to T cell metabolism and anti-tumor immune response

Researchers at The University of Texas MD Anderson Cancer Center have discovered that a protein called NF-kappa B-inducing kinase (NIK) is essential for the shift in metabolic activity that occurs with T cell activation, making it a critical factor in regulating the anti-tumor immune response.

4 Jan 2021

USF researchers discover promising new compound to open constricted airways

Despite the progress made in managing asthma and chronic obstructive pulmonary disease (COPD), poorly controlled symptoms for both respiratory diseases can lead to severe shortness of breath, hospitalizations or even death.

4 Jan 2021

P2 COVID-19 study shows no material safety differences between opaganib and control arms

Preliminary data from the non-powered U.S. Phase 2 study of 40 hospitalized patients shows that orally-administered opaganib was safe, with no material safety differences between opaganib and control arms.

4 Jan 2021

New tool may help monitor serotonin transmission with greater fidelity than current methods

Serotonin is a neurochemical that plays a critical role in the way the brain controls our thoughts and feelings.

23 Dec 2020

Phase 2/3 COVID-19 study evaluates safety, potential identification of preliminary efficacy signals

Top-line data from the 270-patient global Phase 2/3 COVID-19 study expected Q1/2021. Top-line data from the 40-patient U.S. Phase 2 study of opaganib in severe COVID-19 expected in the coming days; this non-powered study was designed to evaluate safety and potential identification of preliminary efficacy signals in support of the global Phase 2/3 study of opaganib.

23 Dec 2020

Truncating mutation locations tied to diversity, severity of autism symptoms

One of the most recognizable characteristics of autism is an amazing diversity of associated behavioral symptoms. Clinicians view autism as a broad spectrum of related disorders, and the origin of the disease's heterogeneity has puzzled scientists, doctors, and affected families for decades.

22 Dec 2020

First patient enrolled in Phase II clinical trial of stem cell therapy for traumatic injuries

The first patient has enrolled in a Phase II clinical trial evaluating a stem cell therapy for the potential early treatment of traumatic injuries and their subsequent complications at The University of Texas Health Science Center at Houston.

21 Dec 2020

Moffitt study may lead to potential treatment options for cutaneous T cell lymphoma

Cutaneous T cell lymphomas (CTCLs) are a group of non-Hodgkin lymphomas that develop from T cells and mainly impact the skin with painful lesions.

21 Dec 2020

Preclinical News and Research

Master Regulator proteins control cancer transcriptional identity

Study: 20% of glioblastomas are fueled by overactive mitochondria

International consortium awarded SNSF Sinergia grant to improve treatment for pediatric brain tumors

RNA sequencing data reveals three major molecular subtypes of Alzheimer's disease

Study opens the way for a potential new cure for children with hard-to-treat neuroblastoma

MD Anderson and Xencor to develop novel antibody therapeutics to treat cancer patients

CytoDel successfully delivers neuronal antibody in animal models of botulism

Repurposed drug can treat hearing loss in humans

Understanding traumatic brain injury in women

Main bioactive compound of ginger root may protect against autoimmune disease progression

Are SARS-CoV-2 antibodies associated with disease enhancement?

Researchers test the effects of growth molecules exuded by oral bacteria

Researchers discover protein crucial to T cell metabolism and anti-tumor immune response

USF researchers discover promising new compound to open constricted airways

P2 COVID-19 study shows no material safety differences between opaganib and control arms

New tool may help monitor serotonin transmission with greater fidelity than current methods

Phase 2/3 COVID-19 study evaluates safety, potential identification of preliminary efficacy signals

Truncating mutation locations tied to diversity, severity of autism symptoms

First patient enrolled in Phase II clinical trial of stem cell therapy for traumatic injuries

Moffitt study may lead to potential treatment options for cutaneous T cell lymphoma

New Approach Methodologies, the 3Rs and Multimodal Imaging in Preclinical Research - eBook eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics